Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system

2005 ◽  
Vol 85 (1) ◽  
pp. 45-50 ◽  
Author(s):  
Kristoph Jahnke ◽  
Eckhard Thiel ◽  
Peter Martus ◽  
Stefan Schwartz ◽  
Agnieszka Korfel
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Prognostic Factors ◽  
Retrospective Study ◽  
Hodgkin Lymphoma ◽  
Non Hodgkin Lymphoma ◽  
The Central Nervous System

scholarly journals The Role of Rituximab in the Treatment of Primary Central Nervous System Lymphoma

Cancers ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1920
Author(s):  
Ruben Van Dijck ◽  
Jeanette K. Doorduijn ◽  
Jacoline E.C. Bromberg
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Hodgkin Lymphoma ◽  
Central Nervous System Lymphoma ◽  
High Dose ◽  
Non Hodgkin Lymphoma ◽  
The Central Nervous System ◽  
Cd20 Antibody ◽  
Anti Cd20

Primary central nervous system lymphoma (PCNSL) is a type of non-Hodgkin lymphoma limited to the central nervous system. It has a poor prognosis. Consensus has been reached on the treatment of newly diagnosed patients with high-dose methotrexate-based chemotherapy, but whether the addition of the monoclonal anti-CD20 antibody rituximab improves survival, as it does in systemic B-cell non-Hodgkin lymphoma, remains disputed. In this review, we reflect on the available evidence of the use of rituximab in PCNSL. Whether rituximab has any beneficial effect remains uncertain.

scholarly journals RARE-29. PRIMARY CENTRAL NERVOUS SYSTEM NON-HODGKIN LYMPHOMA IN AN 11-YEAR-OLD BOY: A CASE REPORT

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii448-iii448
Author(s):  
Jorge Luis Ramírez-Melo ◽  
Regina M Navarro-Martin del Campo ◽  
Manuel D Martinez-Albarran ◽  
Fernando Sánchez-Zubieta ◽  
Ana L Orozco-Alvarado ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Hodgkin Lymphoma ◽  
Central Nervous System Lymphoma ◽  
Complete Response ◽  
High Dose ◽  
Illustrative Case ◽  
Tumor Biopsy ◽  
Non Hodgkin Lymphoma ◽  
The Right

Abstract BACKGROUND Primary central nervous system lymphoma (PCNSL) are very rare in children. CLINICAL CASE: An 11-year-old male presented with a 2 months history with myoclonic movements in the upper right limb, and a sudden frontal headache, gait disturbance due to right hemiparesis and an ipsilateral convulsive episode. Upon admission he had critical condition, with hypertensive skull syndrome, Glasgow of 12, Karnofsky 40%, right hemiparesis, swallowing disorder, facial paralysis, and loss of photo motor reflex and unilateral amaurosis. A CT and MRI showed a huge tumor mass in the left tempo-parietal region, infiltrating the white matter and shifting the midline. A Tumor biopsy was done, and reported diffuse small cell non-Hodgkin lymphoma of high-grade, Burkitt type. Systemic lymphoma workup was negative. He received six cycles of chemotherapy based on high dose methotrexate, rituximab and triple intrathecal.After the second cycle an ophthalmologic evaluation was done, and found infiltration to the right retina, for which 6 cycles of intra vitreous chemotherapy with methotrexate were applied, he showed an excellent response, and recovered all his neurological functions except that right hemianopia persist. Control MRI showed partial response at 2nd cycle and complete response after the 4th cycle. No Radiation was performed. CONCLUSION This report highlights the fact that pediatric PCNSL may be effectively treated by a combination of HDMTX and rituximab-based chemoimmunotherapy without irradiation. Lack of awareness of this rare entity may lead to extense resections of brain, and potential permanent secuelae that were avoided in this illustrative case.

The Role of Radiation Therapy in the Management of Primary Non-Hodgkin Lymphomas of the Central Nervous System: Clinical Study of 10 Cases

1986 ◽  
Vol 72 (6) ◽  
pp. 565-573 ◽  
Author(s):  
Adriano Di Marco ◽  
Luisa Rosta ◽  
Franco Campostrini ◽  
Andrea Bonetti ◽  
Mario Palazzi ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Radiation Therapy ◽  
Whole Brain Irradiation ◽  
Brain Irradiation ◽  
Non Hodgkin Lymphoma ◽  
Uncommon Disease ◽  
The Central Nervous System ◽  
Disseminated Disease ◽  
Clinical Conditions

A series of 10 patients with a primary non-Hodgkin lymphoma of the central nervous system were observed and treated by the authors. All were diagnosed after a pathologic examination of the surgical material; the lesions were supratentorial in all cases and unifocal in 9. In every case radiation therapy improved clinical conditions and in most cases even radiologic features of the patients. Four patients were alive and without evidence of disease many months after therapy. Four patients died with a relapse in the central nervous system; 3 of them had disseminated disease at the time of death. Two patients died for an unknown cause. Radiation therapy was performed with 60Co source with 2 opposed portals and the whole brain irradiation technique in all cases but 2. Doses ranged from 35 to 54 Gy. The recent literature on this uncommon disease and the most adequate therapeutic possibilities of radiation therapy and chemotherapy, or both, are discussed.

Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment

Blood ◽  
2003 ◽  
Vol 101 (2) ◽  
pp. 466-468 ◽  
Author(s):  
James L. Rubenstein ◽  
Dan Combs ◽  
Jay Rosenberg ◽  
Arthur Levy ◽  
Michael McDermott ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Hodgkin Lymphoma ◽  
Phase 1 ◽  
Central Nervous System Lymphoma ◽  
Serum Levels ◽  
Pharmacokinetic Analysis ◽  
Lymphomatous Meningitis ◽  
Cell Surface Molecule ◽  
Non Hodgkin Lymphoma

Most lymphomas that involve the central nervous system are B-cell neoplasms that express the cell surface molecule CD20. After intravenous administration, rituximab can be reproducibly measured in the cerebrospinal fluid (CSF) in patients with primary central nervous system lymphoma; however, the CSF levels of rituximab are approximately 0.1% of serum levels associated with therapeutic activity in patients with systemic non-Hodgkin lymphoma. Because lymphomatous meningitis is a frequent complication of non-Hodgkin lymphoma, we have conducted an analysis of the safety and pharmacokinetics of direct intrathecal administration of rituximab using cynomolgus monkeys. No significant acute or delayed toxicity, neurologic or otherwise, was detected. Pharmacokinetic analysis suggests that drug clearance from the CSF is biphasic, with a terminal half-life of 4.96 hours. A phase 1 study to investigate the safety and pharmacokinetics of intrathecal rituximab in patients with recurrent lymphomatous meningitis will be implemented based on these findings.

Principles of paediatric radiation oncology

2013 ◽  
Author(s):  
Roger E Taylor
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Hodgkin Lymphoma ◽  
Radiation Oncology ◽  
Intensity Modulated Radiotherapy ◽  
Primitive Neuroectodermal Tumour ◽  
Paediatric Tumours ◽  
Intensity Modulated ◽  
Non Hodgkin Lymphoma ◽  
Central Nervous System Tumours

Chapter 15 discusses the principles of paediatric radiation oncology, and addresses quality assurance, chemotherapy/radiotherapy interactions, Leukaemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, Neuroblastoma, Rhabdomyosarcoma, Ewing’s sarcoma/peripheral primitive neuroectodermal tumour, Osteosarcoma, central nervous system tumours, Intensity-modulated radiotherapy, and proton therapy for paediatric tumours.

Sign in / Sign up

Export Citation Format

Share Document